CAT confirms new CEO

Cambridge Antibody Tech Group PLC
8 April 2002


02/CAT/16

FOR IMMEDIATE RELEASE

Monday 8 April 2002

For Further Information Contact:

Cambridge Antibody Technology              Weber Shandwick Square Mile (Europe)

Tel: [phone]                  Tel: [phone]

John Aston, Finance Director               Kevin Smith

Rowena Gardner, Head of Corporate          Graham Herring
Communications
                                           BMC Communications/The Trout Group (USA)

                                           Tel: [phone]

                                           Brad Miles, ext 17 (media)

                                           Brandon Lewis, ext.15 (investors)



                     CAMBRIDGE ANTIBODY TECHNOLOGY CONFIRMS

                   APPOINTMENT OF NEW CHIEF EXECUTIVE OFFICER

Melbourn, UK... Cambridge Antibody Technology (LSE: CAT; NASDAQ: CATG) is
pleased to confirm that Mr Peter Chambre was formally appointed as a director
and Chief Executive Officer of the Company with effect from the commencement of
business today.

In respect of the appointment of a new director, Rule 16.4 of Listing Rules
requires disclosure of all directorships held in any other publicly quoted
companies at any time in the past five years. Mr Chambre is not currently a
director of any other publicly quoted company either in the UK or elsewhere. He
was a director of Bespak plc from 9 March 1994 to 29 July 2000.

None of the other disclosure requirements relating to Rule 16.4 of the Listing
Rules are relevant to Mr Chambre.

Neither Mr Chambre nor his immediate family nor any connected person hold any
securities that are, or are to be, listed in the Company pursuant to section 324
and 328 of the Companies Act 1985 or entered in the Company's register in
accordance with section 325 (3) or (4) of that Act and accordingly no further
disclosure requirement arises pursuant to Rule 16.13 of the Listing Rules.



                                     -ENDS-



Cambridge Antibody Technology (CAT)

  • CAT is a UK biotechnology company using its proprietary technologies in
    human monoclonal antibodies for drug discovery and drug development. Based
    near Cambridge, England, CAT currently employs around 270 people.
  • CAT is listed on the London Stock Exchange and has been listed on NASDAQ
    since June 2001. CAT raised £41m in its IPO in March 1997 and £93m in a
    secondary offering in April 2000.
  • CAT has an advanced platform technology for rapidly isolating human
    monoclonal antibodies using phage display systems. CAT has extensive phage
    antibody libraries, currently incorporating more than

  • 100 billion distinct antibodies. These libraries form the basis for the
    Company's strategy to develop a portfolio of antibody-based drugs and to
    utilise antibodies as tools for target validation. Six human therapeutic
    antibodies developed by CAT are at various stages of clinical trials.

  • CAT has alliances with a large number of biotechnology and pharmaceutical
    companies to discover, develop and commercialise human monoclonal
    antibody-based products. CAT has also licensed its proprietary human
    antibody phage display libraries to several companies for target validation
    and drug discovery. CAT's collaborators include: Abbott, AMRAD, Elan, Eli
    Lilly, Genetics Institute, Genzyme, Human Genome Sciences, Immunex, Incyte,
    Merck & Co., Inc, Oxford GlycoSciences, Pharmacia, Pfizer, Wyeth-Ayerst,
    Xerion and Zyomyx.



Application of the Safe Harbor of the Private Securities Litigation Reform Act
of 1995: This press release contains statements about Cambridge Antibody
Technology Group plc ("CAT") that are forward looking statements. All statements
other than statements of historical facts included in this press release may be
forward looking statements within the meaning of Section 21E of the Securities
Exchange Act of 1934.

These forward looking statements are based on numerous assumptions regarding
CAT's present and future business strategies and the environment in which CAT
will operate in the future. Certain factors that could cause CAT's actual
results, performance or achievements to differ materially from those in the
forward looking statements include: market conditions, CAT's ability to enter
into and maintain collaborative arrangements, success of product candidates in
clinical trials, regulatory developments and competition.



                      This information is provided by RNS
            The company news service from the London Stock Exchange